FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W193461371> ?p ?o ?g. }

• W193461371 endingPage "2756" @default.
• W193461371 startingPage "2747" @default.
• W193461371 abstract "Abstract All-trans retinoic acid (tRA) is a potent differentiation agent that is effective therapy for acute promyelocytic leukemia (APL). However, 5% to 25% of patients develop retinoic acid syndrome, a potentially life-threatening complication in which the pathogenesis relates to adhesive alterations of APL cells. Therefore, we investigated the relationship between tRA-induced differentiation and the adhesive properties of APL cells. After confirming differentiation-related morphological changes of NB-4 cells in response to tRA, we showed that homotypic aggregation of NB-4 cells grown in tRA for 72 hours is dose-dependent with a median effective dose of approximately 50 nmol/L. Maximal aggregation occurred at mean and peak therapeutic serum concentrations (100 and 1,000 nmol/L, respectively). Aggregation also increased with the length of tRA exposure over 168 hours. Aggregation was inhibited by neutralizing antibodies against LFA-1 and ICAM-2. Notably, antibodies directed against VLA-4, other β2 integrins (Mac-1 and p150), or other potential LFA-1 counterstructures that were expressed on the cell surface (ICAM-1 and ICAM-3) did not block aggregation. Aggregation occurred with similar kinetics regardless of the presence of phorbol ester or the “activating” monoclonal antibody (MoAb) KIM 185, suggesting that the avidity of LFA-1 is not modulated on NB-4 cells in a manner similar to other leukocytes. Consistent with the prompt clinical effectiveness of methyl prednisolone sodium succinate (MPSS) in retinoic acid syndrome, MPSS rapidly inhibited homotypic aggregation in a dose-dependent manner. Thus, tRA alters the adhesive properties of APL cells by inducing the expression of high-avidity β2 integrins, aggregation is inhibited by LFA-1 and ICAM-2 MoAb, and tRA effects are rapidly reversible by MPSS. Taken together, our findings provide a clinically relevant system for study of LFA-1/ICAM-2 interaction and suggest a mechanism in part for retinoic acid syndrome and the effectiveness of MPSS in ameliorating retinoic acid syndrome." @default.
• W193461371 created "2016-06-24" @default.
• W193461371 creator A5005689123 @default.
• W193461371 creator A5028187863 @default.
• W193461371 creator A5075766799 @default.
• W193461371 date "1997-10-01" @default.
• W193461371 modified "2023-10-16" @default.
• W193461371 title "Retinoic Acid Induces Aggregation of the Acute Promyelocytic Leukemia Cell Line NB-4 by Utilization of LFA-1 and ICAM-2" @default.
• W193461371 cites W1492387747 @default.
• W193461371 cites W1560483300 @default.
• W193461371 cites W1575164560 @default.
• W193461371 cites W1918641683 @default.
• W193461371 cites W1948143034 @default.
• W193461371 cites W1967849433 @default.
• W193461371 cites W1974839297 @default.
• W193461371 cites W1977627834 @default.
• W193461371 cites W1981044274 @default.
• W193461371 cites W1981571305 @default.
• W193461371 cites W1983427404 @default.
• W193461371 cites W1983547790 @default.
• W193461371 cites W1990312495 @default.
• W193461371 cites W1995811820 @default.
• W193461371 cites W1996796460 @default.
• W193461371 cites W1999574260 @default.
• W193461371 cites W2001163176 @default.
• W193461371 cites W2004041373 @default.
• W193461371 cites W2007831455 @default.
• W193461371 cites W2008566974 @default.
• W193461371 cites W2010809868 @default.
• W193461371 cites W2014151262 @default.
• W193461371 cites W2016523110 @default.
• W193461371 cites W203086379 @default.
• W193461371 cites W2037986253 @default.
• W193461371 cites W2046657068 @default.
• W193461371 cites W2066367871 @default.
• W193461371 cites W2073535823 @default.
• W193461371 cites W2076625163 @default.
• W193461371 cites W2079096224 @default.
• W193461371 cites W2079895278 @default.
• W193461371 cites W2088873595 @default.
• W193461371 cites W2099675490 @default.
• W193461371 cites W2102826458 @default.
• W193461371 cites W2122744441 @default.
• W193461371 cites W2156116410 @default.
• W193461371 cites W2157279574 @default.
• W193461371 cites W2176563609 @default.
• W193461371 cites W2177562606 @default.
• W193461371 cites W2339616204 @default.
• W193461371 cites W2407345634 @default.
• W193461371 cites W2416338867 @default.
• W193461371 cites W2418912569 @default.
• W193461371 cites W2443384920 @default.
• W193461371 cites W4230693812 @default.
• W193461371 cites W4232002706 @default.
• W193461371 cites W4239565845 @default.
• W193461371 cites W4298273896 @default.
• W193461371 cites W43972213 @default.
• W193461371 doi "https://doi.org/10.1182/blood.v90.7.2747" @default.
• W193461371 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9326242" @default.
• W193461371 hasPublicationYear "1997" @default.
• W193461371 type Work @default.
• W193461371 sameAs 193461371 @default.
• W193461371 citedByCount "94" @default.
• W193461371 countsByYear W1934613712012 @default.
• W193461371 countsByYear W1934613712014 @default.
• W193461371 countsByYear W1934613712016 @default.
• W193461371 countsByYear W1934613712017 @default.
• W193461371 countsByYear W1934613712019 @default.
• W193461371 countsByYear W1934613712020 @default.
• W193461371 countsByYear W1934613712021 @default.
• W193461371 countsByYear W1934613712022 @default.
• W193461371 countsByYear W1934613712023 @default.
• W193461371 crossrefType "journal-article" @default.
• W193461371 hasAuthorship W193461371A5005689123 @default.
• W193461371 hasAuthorship W193461371A5028187863 @default.
• W193461371 hasAuthorship W193461371A5075766799 @default.
• W193461371 hasBestOaLocation W1934613711 @default.
• W193461371 hasConcept C153911025 @default.
• W193461371 hasConcept C159654299 @default.
• W193461371 hasConcept C185592680 @default.
• W193461371 hasConcept C203014093 @default.
• W193461371 hasConcept C2776601000 @default.
• W193461371 hasConcept C2779963572 @default.
• W193461371 hasConcept C2781121885 @default.
• W193461371 hasConcept C502942594 @default.
• W193461371 hasConcept C54355233 @default.
• W193461371 hasConcept C81885089 @default.
• W193461371 hasConcept C86803240 @default.
• W193461371 hasConceptScore W193461371C153911025 @default.
• W193461371 hasConceptScore W193461371C159654299 @default.
• W193461371 hasConceptScore W193461371C185592680 @default.
• W193461371 hasConceptScore W193461371C203014093 @default.
• W193461371 hasConceptScore W193461371C2776601000 @default.
• W193461371 hasConceptScore W193461371C2779963572 @default.
• W193461371 hasConceptScore W193461371C2781121885 @default.
• W193461371 hasConceptScore W193461371C502942594 @default.
• W193461371 hasConceptScore W193461371C54355233 @default.
• W193461371 hasConceptScore W193461371C81885089 @default.

• next